Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Filtronic

    MCap

    GBP107m

    Last close

    GBP0.49

    ▲ 16.00 (48.48%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Pharnext (PAR: ALPHA)

Last close As at 24/04/2024

EUR0.10

▲ 0.03 (42.86%)

Market capitalisation

1m

Advanced clinical-stage biopharmaceutical, Pharnext, is developing novel therapies for neurodegenerative diseases lacking curative and/or disease-modifying treatments. PXT3003 for Charcot-Marie-Tooth disease type 1A (CMT1A) is in advanced Phase III clinical trials with top-line data due in Q423.

Latest Insights

View More

Healthcare | Flash note

Pharnext — Potential licensing deals could add confidence

Healthcare | Update

Pharnext — Improving FY23 financial footing

Update

Pharnext — Revised legal structure to offer operational stability

Healthcare | Flash note

Pharnext — Neovacs trust to manage Pharnext deal
Visit Website

Sector

Healthcare

Key Management

  • Hugo Brugiere

    Chairman & CEO

Balance Sheet

Forecast net debt (€m)

42.6

Forecast gearing ratio (%)

79

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (87.2) (99) (99)
Relative (88) (99) (99)
52 week high/low €0.2/€0.0

Financials

Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 3.6 (22.2) (30.6) (100.67) N/A N/A
2022A 2.3 (27.2) (38.5) (16.66) N/A N/A
2023E 1.9 (23.7) (24.7) (3579.47) N/A N/A
2024E 8.9 (10.8) (13.2) (1910.77) N/A N/A

Research

Update

Healthcare

Pharnext — Approaching clinical validation

Flash note

Healthcare

Pharnext — €12m loan to ease funding overhang

Healthcare

research

Pharnext — Neovacs €2.5m loan part of a potential larger deal

Flash note

Healthcare

Pharnext — PREMIER trial completes patient recruitment

Update

Healthcare

Pharnext — Convertible debt terms revised

Update

Healthcare

Pharnext — Clinically healthy

Update

Healthcare

Pharnext — Back in the saddle again

Update

Healthcare

Pharnext — Pivotal Phase III initiated

Update

Healthcare

Pharnext — R&D day highlights

edison tv

Healthcare

Pharnext – executive interview

Initiation

Healthcare

Pharnext — New efficacy and new indications from old drugs

thematic

Healthcare

Machine learning in drug development

thematic

Healthcare

Outlook for 2023: Biotechs remain central to novel drug development
Cancer cells

thematic

Healthcare

Oncology ABCs (part four): Blood cancers (AML) – notable innovations
cell DNA double helix

thematic

Healthcare

Cell and gene therapies

thematic

Healthcare

Drug delivery platforms

thematic

Healthcare

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

Neuroscience comeback

thematic

Consumer

IPO apocalypse

thematic

Healthcare

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

ESG, moving beyond the box tick

thematic

Healthcare

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

Artificial intelligence in drug discovery

thematic

Healthcare

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Healthcare

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Healthcare

Edison Exhibits- antibiotic development

thematic

Healthcare

The next wave in AMD

thematic

Healthcare

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Healthcare

Drug pricing – Market access and reimbursement

thematic

Healthcare

The diagnostics sector

thematic

Healthcare

ASCO 2017

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Energy & Resources

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

Edison healthcare quarterly: Crisis? What crisis?

thematic

Healthcare

Edison healthcare quarterly: How to please some of the people some of the time